Geovax Labs (OTCMKTS:GOVX) released its earnings results on Friday. The biotechnology company reported $0.00 earnings per share (EPS) for the quarter, Zacks Sales Estimate reports. The business had revenue of $0.18 million for the quarter, compared to analyst estimates of $0.30 million.
Shares of Geovax Labs stock remained flat at $$0.04 during trading hours on Friday. 642,696 shares of the company traded hands, compared to its average volume of 818,667. Geovax Labs has a 1 year low of $0.02 and a 1 year high of $0.10. The company has a market capitalization of $3.01, a PE ratio of -1.20 and a beta of -0.04.
Separately, ValuEngine downgraded shares of Geovax Labs from a “sell” rating to a “strong sell” rating in a research report on Saturday, November 25th.
GeoVax Labs, Inc (GeoVax) is a clinical-stage biotechnology company. The Company is engaged in developing human vaccines against infectious diseases using its modified vaccine Ankara-virus-like particles (MVA-VLP) vaccine platform. The Company’s platform supports in vivo expression of non-infectious virus-like particles (VLPs) from the cells of the person receiving the vaccine.
Receive News & Ratings for Geovax Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geovax Labs and related companies with MarketBeat.com's FREE daily email newsletter.